![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 18, 2021 12:18:00 PM
Why would you even think at 185 million outstanding I would be joking ?
That’s a ridiculous amount of outstanding shares for a non revenue biotech with one drug in the works
Not sure how you look at it ???
However no how you look at it
Yes the institutions are in this and that’s usually a very good sign however the valuation of the company at this stage is ....
appropriate ?
Over valued ?
Under valued ?
Best of luck
Don’t short this
That’s a big mistake
Patiently long here
Lastly ,
Best of luck to you
Recent AMPE News
- Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation • PR Newswire (US) • 04/03/2024 06:33:00 PM
- Ampio Announces Voluntary Delisting and SEC Deregistration • PR Newswire (US) • 03/25/2024 09:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/05/2024 05:15:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 08:49:00 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/28/2024 08:48:05 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/28/2024 08:47:17 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/28/2024 08:46:20 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 02/28/2024 08:45:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 02:31:23 PM
- Ampio Provides Update on Results from Pre-IND Enabling Studies • PR Newswire (US) • 02/14/2024 10:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:31:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/25/2024 09:18:53 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/24/2024 10:16:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:20:20 PM
- Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions • PR Newswire (US) • 01/11/2024 09:15:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/21/2023 09:25:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:10:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 01:30:24 PM
- Ampio Pharmaceuticals to Present at the Emerging Growth Conference • PR Newswire (US) • 10/31/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 06:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 06:56:04 PM
- Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201 • PR Newswire (US) • 10/05/2023 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 08:15:24 PM
- Ampio Pharmaceuticals to Present at the Emerging Growth Conference • PR Newswire (US) • 09/26/2023 01:15:00 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM